Partnership Equips Laboratories and Oncologists with a Foundation for Genomic Data Analysis through to Therapeutic Options
Hawthorne, CA and Lexington, MA – BioDiscovery, Inc., a leader in DNA structural variant analysis laboratory software for copy number (CNV) and sequence variation, and N-of-One, the leading provider of molecular interpretation and therapeutic strategies for precision medicine in oncology, today announced a partnership to jointly provide integrated genomic analysis interpretation solutions. This partnership will bring together integrated, best-in-class components to enable clinicians to use genomic data generated by laboratories more easily and efficiently to identify targeted therapeutic options appropriate for each specific patient as well as better understand the molecular profile of the patient's tumor. Financial terms of the agreement are not disclosed.
Under the terms of the agreement, N-of-One and BioDiscovery will jointly market and sell N-of-One's interpretation solutions and content together with BioDiscovery's genomic analysis software, providing laboratories and oncologists with an integrated platform from genomic data analysis through to therapeutic decision support.
"The number of genomic variants identified as prognostic indicators, or available as possible therapeutic targets, continues to increase at a very fast rate. BioDiscovery's solutions excel at helping cytogenetic and molecular laboratories quickly identify likely actionable variants from the thousands present in typical cancer cases, with a particular emphasis on copy number variants (CNVs) that drive a large number of tumor types but remain difficult to interpret," said Dr. Soheil Shams, CEO, BioDiscovery, Inc. "N-of-One completes the solution by taking this narrowed list and elucidating the possible therapeutic options based on an understanding of these variants in the context of the disease biology."
"We are committed to our mission of enabling precision medicine for clinicians and researchers by providing outstanding molecular interpretation," said Chris Cournoyer, CEO, at N-of-One. "Working with BioDiscovery, developer of genomics visualization and analysis software that is already in use at many cancer centers, hospitals, and independent laboratories, we are able to strengthen the point-of-care by adding a wealth of disease-specific knowledge from the latest research findings and drug trials. This gives oncologists and treating clinicians additional insights into possible therapeutic strategies that are informed by the patient's disease, genomic profile, available therapies and trials, and current research."
A leading provider of genomics software for translational research and clinical settings, BioDiscovery makes the Nexus Copy Number and NxClinical software solutions for confident analysis, visualization, and interpretation of copy number and sequence variation from virtually all genomic microarray and NGS platforms. For more information visit http://www.biodiscovery.com or call 310-414-8100.
N-of-One, a leader in precision medicine for oncology, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinical insights and therapeutic options focused on the point of care. N-of-One's team of experts has interpreted more than 6,000 tumors for oncologists and patients worldwide, through partnerships to provide clinical interpretation for leading diagnostic companies (such as Foundation Medicine and Clarient), through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia), directly to oncologists and through employee access benefit programs (such as Life Technologies). N-of-One does not provide medical advice or promote any product or service. For more information, please visit http://www.n-of-one.com or call 617-202-9808.
+1 (310) 414-8100